Skip to main content
Erschienen in: Tumor Biology 2/2016

21.09.2015 | Original Article

Overexpression of Gremlin promotes non-small cell lung cancer progression

verfasst von: Yunhong Yin, Yie Yang, Liyun Yang, Yan Yang, Chunyu Li, Xiao Liu, Yiqing Qu

Erschienen in: Tumor Biology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Lung cancer is the major cause of cancer-related death worldwide, and 80 % of them are non-small cell lung cancer (NSCLC) cases. Gremlin, a bone morphogenetic protein (BMP) antagonist, is overexpressed in various cancerous tissues; however, little is known about the roles of Gremlin in lung carcinogenesis, and it remains unclear whether Gremlin expression may associate with EGFR-TKI resistance. In this study, expression of Gremlin mRNA and protein in matched tumor and normal lung specimens are quantified by quantitative real-time PCR and western blot. The functional role of Gremlin in NSCLC cells was evaluated by interference RNA (siRNA). The effects of Silenced Gremlin on the resistant PC-9/GR cell line were investigated by proliferation and apoptosis analysis compared with control PC-9 cells. Our results found that Gremlin expression levels were higher in NSCLC tissues, and Gremlin was more highly expressed in PC-9/GR cells compared to PC-9 cells. Knocking down of Gremlin in PC-9/GR cells decreased cell proliferation and increased the expression of BMP7 protein. In addition, Gremlin silencing significantly potentiated apoptosis induced by gefitinib in PC-9/GR with Gremlin knockdown compared to PC-9 transfected with control shRNA, suggesting Gremlin contributes to gefitinib resistance in NSCLC. Gremlin might be explored as a candidate of therapeutic target for modulating EGFR-TKI sensitivity in NSCLC.
Literatur
1.
2.
Zurück zum Zitat Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10). Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10).
3.
Zurück zum Zitat Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51.CrossRefPubMed Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51.CrossRefPubMed
4.
Zurück zum Zitat Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42.CrossRefPubMed Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–42.CrossRefPubMed
5.
Zurück zum Zitat Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.CrossRefPubMed Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–57.CrossRefPubMed
6.
Zurück zum Zitat Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012;13:300–8.CrossRefPubMed Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012;13:300–8.CrossRefPubMed
7.
Zurück zum Zitat Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhasz E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11:521–9.CrossRefPubMed Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhasz E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11:521–9.CrossRefPubMed
8.
Zurück zum Zitat Church RH, Krishnakumar A, Urbanek A, Geschwindner S, Meneely J, Bianchi A, et al. Gremlin1 preferentially binds to bone morphogenetic protein-2 (BMP-2) and BMP-4 over BMP-7. Biochem J. 2015;466(1):55–68.CrossRefPubMed Church RH, Krishnakumar A, Urbanek A, Geschwindner S, Meneely J, Bianchi A, et al. Gremlin1 preferentially binds to bone morphogenetic protein-2 (BMP-2) and BMP-4 over BMP-7. Biochem J. 2015;466(1):55–68.CrossRefPubMed
9.
Zurück zum Zitat Wellbrock J, Harbaum L, Stamm H, Hennigs JK, Schulz B, Klose H, et al. Intrinsic BMP antagonist gremlin-1 as a novel circulating marker in pulmonary arterial hypertension. Lung. 2015;193(4):567–70.CrossRefPubMed Wellbrock J, Harbaum L, Stamm H, Hennigs JK, Schulz B, Klose H, et al. Intrinsic BMP antagonist gremlin-1 as a novel circulating marker in pulmonary arterial hypertension. Lung. 2015;193(4):567–70.CrossRefPubMed
10.
Zurück zum Zitat Rajski M, Saaf A, Buess M. BMP2 response pattern in human lung fibroblasts predicts outcome in lung adenocarcinomas. BMC Med Genomics. 2015;8:16.CrossRefPubMedPubMedCentral Rajski M, Saaf A, Buess M. BMP2 response pattern in human lung fibroblasts predicts outcome in lung adenocarcinomas. BMC Med Genomics. 2015;8:16.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Wang DJ, Zhi XY, Zhang SC, Jiang M, Liu P, Han XP, et al. The bone morphogenetic protein antagonist Gremlin is overexpressed in human malignant mesothelioma. Oncol Rep. 2012;27(1):58–64.PubMed Wang DJ, Zhi XY, Zhang SC, Jiang M, Liu P, Han XP, et al. The bone morphogenetic protein antagonist Gremlin is overexpressed in human malignant mesothelioma. Oncol Rep. 2012;27(1):58–64.PubMed
12.
Zurück zum Zitat Tamminen JA, Parviainen V, Rönty M, Wohl AP, Murray L, Joenväärä S, et al. Gremlin-1 associates with fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor slug. Oncogenesis. 2013;2, e66.CrossRefPubMedPubMedCentral Tamminen JA, Parviainen V, Rönty M, Wohl AP, Murray L, Joenväärä S, et al. Gremlin-1 associates with fibrillin microfibrils in vivo and regulates mesothelioma cell survival through transcription factor slug. Oncogenesis. 2013;2, e66.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Zhang Y, Zhang Q. Bone morphogenetic protein-7 and Gremlin: new emerging therapeutic targets for diabetic nephropathy. Biochem Biophys Res Commun. 2009;383(1):1–3.CrossRefPubMed Zhang Y, Zhang Q. Bone morphogenetic protein-7 and Gremlin: new emerging therapeutic targets for diabetic nephropathy. Biochem Biophys Res Commun. 2009;383(1):1–3.CrossRefPubMed
14.
Zurück zum Zitat Sneddon JB, Zhen HH, Montgomery K, van de Rijn M, Tward AD, West R, et al. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc Natl Acad Sci U S A. 2006;103:14842–7.CrossRefPubMedPubMedCentral Sneddon JB, Zhen HH, Montgomery K, van de Rijn M, Tward AD, West R, et al. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc Natl Acad Sci U S A. 2006;103:14842–7.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Erdmann R, Ozden C, Weidmann J, Schultze A. Targeting the Gremlin-VEGFR2 axis—a promising strategy for multiple diseases? J Pathol. 2015;236(4):403–6.CrossRefPubMed Erdmann R, Ozden C, Weidmann J, Schultze A. Targeting the Gremlin-VEGFR2 axis—a promising strategy for multiple diseases? J Pathol. 2015;236(4):403–6.CrossRefPubMed
16.
Zurück zum Zitat Worthley DL, Churchill M, Compton JT, Tailor Y, Rao M, Si Y, et al. Gremlin 1 identifies a skeletal stem cell with bone, cartilage, and reticular stromal potential. Cell. 2015;160(1–2):269–84.CrossRefPubMedPubMedCentral Worthley DL, Churchill M, Compton JT, Tailor Y, Rao M, Si Y, et al. Gremlin 1 identifies a skeletal stem cell with bone, cartilage, and reticular stromal potential. Cell. 2015;160(1–2):269–84.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Gustafson B, Hammarstedt A, Hedjazifar S, Hoffmann JM, Svensson PA, Grimsby J, et al. BMP4 and BMP antagonists regulate human white and beige adipogenesis. Diabetes. 2015;64(5):1670–81.CrossRefPubMed Gustafson B, Hammarstedt A, Hedjazifar S, Hoffmann JM, Svensson PA, Grimsby J, et al. BMP4 and BMP antagonists regulate human white and beige adipogenesis. Diabetes. 2015;64(5):1670–81.CrossRefPubMed
Metadaten
Titel
Overexpression of Gremlin promotes non-small cell lung cancer progression
verfasst von
Yunhong Yin
Yie Yang
Liyun Yang
Yan Yang
Chunyu Li
Xiao Liu
Yiqing Qu
Publikationsdatum
21.09.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4093-8

Weitere Artikel der Ausgabe 2/2016

Tumor Biology 2/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.